Annual report pursuant to Section 13 and 15(d)

Collaboration Arrangements - Additional Information (Detail)

v2.4.0.6
Collaboration Arrangements - Additional Information (Detail) (USD $)
In Millions, unless otherwise specified
12 Months Ended
Dec. 31, 2012
Dec. 31, 2011
Agreements with Merck KGaA [Member]
   
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]    
Upfront payment received 25  
Milestone payments received 72.5  
Merck's percentage share of worldwide development expenses 70.00%  
Portion of profits that Company is eligible to participate in United States, depending upon total sales 50.00%  
Revenue recognized by the Company 5.9  
Deferred revenue 67.5  
Company earned a reimbursement for eligible worldwide development expenses 13.1  
Agreements with Merck KGaA [Member] | Subsequent event [Member]
   
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]    
Milestone payments received 42.5  
Milestone payments received 42.5  
Agreements with Merck KGaA [Member] | Regulatory and development milestones [Member]
   
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]    
Potential future milestones 112.5  
Agreements with Merck KGaA [Member] | Regulatory and development milestones [Member] | Subsequent event [Member]
   
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]    
Potential future milestones 12.5  
Agreements with Merck KGaA [Member] | Commercialization milestones [Member]
   
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]    
Potential future milestones 340.0  
Agreement with Eleison Pharmaceuticals, Inc [Member]
   
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]    
Percentage of profits from commercialization 50.00%  
Revenue recognized by the Company   $ 0.1